World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
31795
World Ranking
14467
National Ranking
1336

Overview

Johanna C. Bendell is affiliated with the Sarah Cannon Research Institute in the United Kingdom. Their primary fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, Bendell's research focuses extensively on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology, and Cancer Research as subfields.

The scientist's work encompasses multiple main topics, which include:

  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • CAR-T Cell Therapy Research
  • Genetic Factors in Colorectal Cancer

Bendell has contributed to numerous publications, with some of the frequent venues being:

  • Journal of Clinical Oncology (54 publications)
  • Annals of Oncology (16 publications)
  • Clinical Cancer Research (10 publications)
  • Cancer Research (10 publications)
  • Regular and Young Investigator Award Abstracts (7 publications)

Recent significant papers authored or co-authored by Bendell include:

  • "Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer," 2020, New England Journal of Medicine
  • "Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study," 2020, The Lancet Oncology
  • "Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study," 2021, Journal of Clinical Oncology
  • "Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer," 2020, Journal of Clinical Oncology
  • "Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study," 2023, The Lancet Oncology

Bendell collaborates frequently with other researchers in the field. Among the most frequent co-authors are:

  • Manish R. Patel
  • Zev A. Wainberg
  • Gerald S. Falchook
  • Patricia LoRusso
  • Thierry André

Best Publications

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

    Thierry André;Kai-Keen Shiu;Tae Won Kim;Benny Vittrup Jensen

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

    Johanna C. Bendell;Susan M. Domchek;Harold J. Burstein M.D.;Lyndsay Harris

  • Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

    Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge

  • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

    Jeffrey J. Wallin;Johanna C. Bendell;Roel Funke;Mario Sznol

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

  • CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    Yelena Y. Janjigian;Johanna Bendell;Emiliano Calvo;Joseph W. Kim

  • Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    Cathy Eng;Tae Won Kim;Johanna Bendell;Guillem Argilés

  • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

    Ryan B. Corcoran;Chloe E. Atreya;Gerald S. Falchook;Eunice L. Kwak

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.

    Michael S. Lee;Baek Yeol Ryoo;Chih Hung Hsu;Kazushi Numata

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Robin Kate Kelley;Bruno Sangro;William Harris;Masafumi Ikeda

  • Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

    Herbert I. Hurwitz;Nikhil Uppal;Stephanie A. Wagner;Johanna C. Bendell

  • Locally advanced pancreatic cancer.

    Christopher G. Willett;Brian G. Czito;Johanna C. Bendell;David P. Ryan

  • Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Charles S Fuchs;Kohei Shitara;Maria Di Bartolomeo;Sara Lonardi

  • Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

    Roy S Herbst;Hendrik-Tobias Arkenau;Hendrik-Tobias Arkenau;Rafael Santana-Davila;Emiliano Calvo

  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.

    Srinevas K. Reddy;Michael A. Morse;Herbert I. Hurwitz;Johanna C. Bendell

  • A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

    Robin M.J.M. Van Geel;Josep Tabernero;Elena Elez;Johanna C. Bendell

Frequent Co-Authors

Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
Herbert Hurwitz
Herbert Hurwitz Duke University
Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Patrick A. Ott
Patrick A. Ott Harvard University
Patricia LoRusso
Patricia LoRusso Yale University
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Yung-Jue Bang
Yung-Jue Bang Seoul National University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternatives to the traditional path of studying medicine in the USA can open doors to diverse and rewarding healthcare careers. If you’re interested in nursing but prefer to avoid extensive entrance exams, consider enrolling in an lpn school without teas test. These programs remove common entry hurdles, making nursing more accessible.

For those more focused on the administrative side of healthcare, earning a healthcare administration online degree provides flexible learning and the skills needed for leadership roles in hospitals, clinics, and other health organizations.

Registered nurses looking to advance their clinical expertise may benefit from an adn to fnp bridge program. These online pathways allow RNs to earn a master’s degree and become Family Nurse Practitioners, expanding both their scope of practice and career opportunities.

Lastly, if your passion is in promoting healthy lifestyles, you can qualify as a nutrition professional with an online nutritionist degree. These programs blend foundational science with practical training—preparing graduates for work in wellness, community health, or private practice.

Best Scientists Citing Johanna C. Bendell

Trending Scientists